Skip to content
Screener

10x Genomics, Inc. TXG Instruments — Revenue

Other product segments

Products and services revenue
$149.09M+2.7%
Services
$10.68M+26.0%
Spatial
$4.57M-47.8%
Single Cell
$3.09M-46.1%
License and royalty revenue
$1.94M-93.0%

Similar metrics at other companies

TEC
TECHInstruments — Revenue
$27.66M+5.9%
ALM
ALMRInstruments — Revenue
$7.38M+78.0%
WAT
WATInstrument Systems — Revenue
$376M+43.0%
Neogen logo
NEOGVeterinary Instruments And Disposables — Revenue
$15.5M0.0%
HRO
HROWOther Revenues — Revenue
$73K-15.1%
Oracle logo
ORCLCloud Revenues — Revenue
$9.91B+47.1%

Other financials

Income statement

See full
Revenue$151.0M-12.6%
Gross profit$112.5M-10.1%
Operating income-$19.6M-165%
Net income-$17.9M-152%
EPS (diluted)-$0.14-150%

Balance sheet

See full
Cash & equivalents$502.5M+26.4%
Total debt$78.8M-9.2%
Total equity$825.5M+6.8%
Total assets$1.0B+5.1%

Cash flow

See full
Operating cash flow$17.0M-4.1%
CapEx$1.6M+0.6%
Free cash flow$15.4M-4.6%

Valuation

See full
Market cap$5.79B+271%
Enterprise value$5.37B+330%
P/S9.4×+7.0×

Profitability

See full
Gross margin70%+0.5pp
Operating margin-14.3%-1.1pp
Net margin-12.2%-0.8pp
FCF margin19.7%+10.9pp

Returns & leverage

See full
Return on equity-9.4%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.7×-0.1×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054491
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Instruments
Single Cell$3,087$5,727$8,310$11,640
Spatial4,5748,77010,61317,672
Total instruments revenue7,66114,49718,92329,312
Consumables
Single Cell88,45185,788177,345169,897
Spatial42,30136,39783,20867,644
Total consumables revenue130,752122,185260,553237,541

Item 1. Financial Statements (Unaudited)

FAQ

What is 10x Genomics, Inc.'s instruments — revenue?
10x Genomics, Inc. (TXG) reported instruments — revenue of $7.66M in Q2 2026.
How has 10x Genomics, Inc.'s instruments — revenue changed year-over-year?
10x Genomics, Inc.'s instruments — revenue decreased by 47.2% year-over-year, from $14.5M to $7.66M.
What is the long-term trend for 10x Genomics, Inc.'s instruments — revenue?
Over 4 years (2021 to 2025), 10x Genomics, Inc.'s instruments — revenue has grown at a -3.1% compound annual growth rate (CAGR), from $64.47M to $56.78M.
What does instruments — revenue mean?
This metric represents the total gross revenue generated from the sale of hardware and instrumentation platforms within the company's product portfolio. It serves as a key indicator of the company's installed base growth and market penetration for its primary technology systems. Tracking this revenue stream helps investors assess the adoption rate of the company's core analytical hardware among research and clinical customers.

Ask your AI about 10x Genomics, Inc.'s instruments — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude